Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Spero Therapeutics (SPRO) EBITDA (2016 - 2025)

Historic EBITDA for Spero Therapeutics (SPRO) over the last 10 years, with Q3 2025 value amounting to -$7.9 million.

  • Spero Therapeutics' EBITDA rose 5742.48% to -$7.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$46.8 million, marking a year-over-year decrease of 1042044.94%. This contributed to the annual value of -$73.4 million for FY2024, which is 42167.41% down from last year.
  • According to the latest figures from Q3 2025, Spero Therapeutics' EBITDA is -$7.9 million, which was up 5742.48% from -$2.4 million recorded in Q2 2025.
  • Spero Therapeutics' EBITDA's 5-year high stood at $51.2 million during Q4 2023, with a 5-year trough of -$32.8 million in Q1 2022.
  • In the last 5 years, Spero Therapeutics' EBITDA had a median value of -$14.0 million in 2024 and averaged -$8.8 million.
  • Its EBITDA has fluctuated over the past 5 years, first soared by 21884.43% in 2021, then crashed by 48012.48% in 2024.
  • Spero Therapeutics' EBITDA (Quarter) stood at -$29.2 million in 2021, then surged by 191.56% to $26.8 million in 2022, then surged by 91.22% to $51.2 million in 2023, then crashed by 142.44% to -$21.7 million in 2024, then skyrocketed by 63.56% to -$7.9 million in 2025.
  • Its EBITDA was -$7.9 million in Q3 2025, compared to -$2.4 million in Q2 2025 and -$14.7 million in Q1 2025.